Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Lymphoma, Follicular 2Urinary Bladder Neck Obstruction 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Renal Insufficiency 1Prostatic Neoplasms 1Prostatic Hyperplasia 1Primary Myelofibrosis 1Polycythemia Vera 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Cancer Recurrent 1Obesity 1Neoplasms 1Myeloproliferative Disorders 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, B-Cell 1Lung Neoplasms 1Lower Urinary Tract Symptoms 1Erectile Dysfunction 1Dendritic Cell Sarcoma, Interdigitating 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

fludarabine phosphate 25Cyclophosphamide 24Peripheral Blood Stem Cell Transplantation 23Busulfan 17Tacrolimus 15Methotrexate 13Cyclosporine 13ruxolitinib 12Whole-Body Irradiation 12Mycophenolic Acid 12Antilymphocyte Serum 11Filgrastim 8Decitabine 7fludarabine 6Etoposide 611-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 6peginterferon alfa-2a 5Radiotherapy 5Methylprednisolone 5Cytarabine 5Carboplatin 5Prednisone 4Melphalan 4Flow Cytometry 4Biopsy 4Aspirin 4givinostat hydrochloride 3givinostat 3bomedemstat 3anagrelide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thrombocythemia, Essential × mirabegron × Clear all
NCT02311569 2019-05-15

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Swiss Cancer Institute

Phase 2 Completed
39 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡